Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy

HomeCirculationVol. 149, No. 15Right Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextRight Ventricular Bone-Avid Tracer Uptake: A Novel Risk Marker in Transthyretin Amyloid Cardiomyopathy Sharmila Dorbala Sharmila DorbalaSharmila Dorbala Correspondence to: Sharmila Dorbala, MD, MPH, Professor of Radiology, Harvard Medical School, Director of Nuclear Cardiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. Email E-mail Address: [email protected] https://orcid.org/0000-0003-1462-1185 Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Cardiac Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. Originally published8 Apr 2024https://doi.org/10.1161/CIRCULATIONAHA.124.067985Circulation. 2024;149:1169–1171This article is a commentary on the followingClinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid CardiomyopathyFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 1171.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Sharmila Dorbala, MD, MPH, Professor of Radiology, Harvard Medical School, Director of Nuclear Cardiology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115. Email sdorbala@bwh.harvard.eduREFERENCES1. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.Circulation. 2016; 133:2404–2412. doi: 10.1161/CIRCULATIONAHA.116.021612LinkGoogle Scholar2. Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis.J Nucl Cardiol. 2019; 26:158–173. doi: 10.1007/s12350-018-01552-4CrossrefMedlineGoogle Scholar3. Porcari A, Fontana M, Canepa M, Biagini E, Cappelli F, Gagliardi C, Longhi S, Pagura L, Tini G, Dore F. Clinical and prognostic implications of right ventricular uptake on bone scintigraphy in transthyretin amyloid cardiomyopathy.Circulation. 2024; 149:1157–1168. doi: 10.1161/CIRCULATIONAHA.123.066524LinkGoogle Scholar4. Cappelli F, Porciani MC, Bergesio F, Perlini S, Attana P, Moggi Pignone A, Salinaro F, Musca F, Padeletti L, Perfetto F. Right ventricular function in AL amyloidosis: characteristics and prognostic implication.Eur Heart J Cardiovasc Imaging. 2012; 13:416–422. doi: 10.1093/ejechocard/jer289CrossrefMedlineGoogle Scholar5. Tomasoni D, Adamo M, Porcari A, Aimo A, Bonfioli GB, Castiglione V, Franzini M, Inciardi RM, Khalil A, Lombardi CM, et al. Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis.Eur Heart J Cardiovasc Imaging. 2023; 24:1405–1414. doi: 10.1093/ehjci/jead145CrossrefMedlineGoogle Scholar6. Datar Y, Clerc OF, Cuddy SAM, Kim S, Taylor A, Neri JC, Benz DC, Bianchi G, Yee AJ, Sanchorawala V, et al. Quantification of right ventricular amyloid burden with 18F-florbetapir PET/CT and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis [published online January 9, 2024]. Eur Heart J Cardiovasc Imaging. doi: 10.1093/ehjci/jead350. https://academic.oup.com/ehjcimaging/advance-article-abstract/doi/10.1093/ehjci/jead350/7513293CrossrefGoogle Scholar7. Dorbala S, Park MA, Cuddy S, Singh V, Sullivan K, Kim S, Falk RH, Taqueti VR, Skali H, Blankstein R, et al. Absolute quantitation of cardiac (99m)Tc-pyrophosphate using cadmium-zinc-telluride-based SPECT/CT.J Nucl Med. 2021; 62:716–722. doi: 10.2967/jnumed.120.247312CrossrefMedlineGoogle Scholar8. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.N Engl J Med. 2018; 379:1007–1016. doi: 10.1056/NEJMoa1805689CrossrefMedlineGoogle Scholar9. Gillmore JD, Judge DP, Cappelli F, Fontana M, Garcia-Pavia P, Gibbs S, Grogan M, Hanna M, Hoffman J, Masri A, et al; ATTRibute-CM Investigators. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy.N Engl J Med. 2024; 390:132–142. doi: 10.1056/NEJMoa2305434CrossrefMedlineGoogle Scholar10. Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceicao I, Di Carli M, Solomon SD, Chen C, Yureneva E, et al. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy [published online February 6, 2024]. Eur J Heart Fail. doi: 10.1002/ejhf.3138. https://onlinelibrary.wiley.com/doi/10.1002/ejhf.3138CrossrefGoogle Scholar11. Coelho T, Marques W, Dasgupta NR, Chao CC, Parman Y, Franca MC, Guo YC, Wixner J, Ro LS, Calandra CR, et al; NEURO-TTRansform Investigators. Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy.JAMA. 2023; 330:1448–1458. doi: 10.1001/jama.2023.18688CrossrefMedlineGoogle Scholar12. Garcia-Pavia P, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid.N Engl J Med. 2023; 389:239–250. doi: 10.1056/NEJMoa2303765CrossrefMedlineGoogle Scholar13. Rettl R, Wollenweber T, Duca F, Binder C, Cherouny B, Dachs TM, Camuz Ligios L, Schrutka L, Dalos D, Beitzke D, et al. Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.Eur Heart J Cardiovasc Imaging. 2023; 24:1019–1030. doi: 10.1093/ehjci/jead030CrossrefMedlineGoogle Scholar14. Fontana M, Martinez-Naharro A, Chacko L, Rowczenio D, Gilbertson JA, Whelan CJ, Strehina S, Lane T, Moon J, Hutt DF, et al. Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression.JACC Cardiovasc Imaging. 2021; 14:189–199. doi: 10.1016/j.jcmg.2020.07.043CrossrefMedlineGoogle Scholar15. Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceicao I, Weiler M, Berk JL, Gertz M, Gillmore JD, et al. Effect of eplontersen on cardiac structure and function in patients with hereditary transthyretin amyloidosis [published online December 7, 2023]. J Card Fail. doi: 10.1016/j.cardfail.2023.11.016. https://onlinejcf.com/article/S1071-9164(23)00894-1/abstractCrossrefGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesClinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid CardiomyopathyAldostefano Porcari, et al. Circulation. 2024;149:1157-1168 April 9, 2024Vol 149, Issue 15 Advertisement Article InformationMetrics © 2024 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.124.067985PMID: 38588337 Originally publishedApril 8, 2024 KeywordsEditorialscardiomyopathiestomography, emission-computed, single-photontransthyretinPDF download Advertisement SubjectsDiagnostic TestingNuclear Cardiology and PETPrognosis